Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 182

1.

Efficacy of a Plasmodium vivax malaria vaccine using ChAd63 and modified vaccinia Ankara expressing thrombospondin-related anonymous protein as assessed with transgenic Plasmodium berghei parasites.

Bauza K, Malinauskas T, Pfander C, Anar B, Jones EY, Billker O, Hill AV, Reyes-Sandoval A.

Infect Immun. 2014 Mar;82(3):1277-86. doi: 10.1128/IAI.01187-13. Epub 2013 Dec 30.

2.

Evaluation of Plasmodium vivax Cell-Traversal Protein for Ookinetes and Sporozoites as a Preerythrocytic P. vivax Vaccine.

Alves E, Salman AM, Leoratti F, Lopez-Camacho C, Viveros-Sandoval ME, Lall A, El-Turabi A, Bachmann MF, Hill AV, Janse CJ, Khan SM, Reyes-Sandoval A.

Clin Vaccine Immunol. 2017 Apr 5;24(4). pii: e00501-16. doi: 10.1128/CVI.00501-16. Print 2017 Apr.

3.

Assessment of the Plasmodium falciparum Preerythrocytic Antigen UIS3 as a Potential Candidate for a Malaria Vaccine.

Longley RJ, Halbroth BR, Salman AM, Ewer KJ, Hodgson SH, Janse CJ, Khan SM, Hill AV, Spencer AJ.

Infect Immun. 2017 Feb 23;85(3). pii: e00641-16. doi: 10.1128/IAI.00641-16. Print 2017 Mar.

4.

Recombinant viral-vectored vaccines expressing Plasmodium chabaudi AS apical membrane antigen 1: mechanisms of vaccine-induced blood-stage protection.

Biswas S, Spencer AJ, Forbes EK, Gilbert SC, Holder AA, Hill AV, Draper SJ.

J Immunol. 2012 May 15;188(10):5041-53. doi: 10.4049/jimmunol.1101106. Epub 2012 Apr 13.

5.

Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals.

Hodgson SH, Ewer KJ, Bliss CM, Edwards NJ, Rampling T, Anagnostou NA, de Barra E, Havelock T, Bowyer G, Poulton ID, de Cassan S, Longley R, Illingworth JJ, Douglas AD, Mange PB, Collins KA, Roberts R, Gerry S, Berrie E, Moyle S, Colloca S, Cortese R, Sinden RE, Gilbert SC, Bejon P, Lawrie AM, Nicosia A, Faust SN, Hill AV.

J Infect Dis. 2015 Apr 1;211(7):1076-86. doi: 10.1093/infdis/jiu579. Epub 2014 Oct 21.

6.

Baculovirus-vectored multistage Plasmodium vivax vaccine induces both protective and transmission-blocking immunities against transgenic rodent malaria parasites.

Mizutani M, Iyori M, Blagborough AM, Fukumoto S, Funatsu T, Sinden RE, Yoshida S.

Infect Immun. 2014 Oct;82(10):4348-57. doi: 10.1128/IAI.02040-14. Epub 2014 Aug 4.

7.

Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors.

Sheehy SH, Duncan CJ, Elias SC, Biswas S, Collins KA, O'Hara GA, Halstead FD, Ewer KJ, Mahungu T, Spencer AJ, Miura K, Poulton ID, Dicks MD, Edwards NJ, Berrie E, Moyle S, Colloca S, Cortese R, Gantlett K, Long CA, Lawrie AM, Gilbert SC, Doherty T, Nicosia A, Hill AV, Draper SJ.

PLoS One. 2012;7(2):e31208. doi: 10.1371/journal.pone.0031208. Epub 2012 Feb 21.

8.

Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure.

Biswas S, Choudhary P, Elias SC, Miura K, Milne KH, de Cassan SC, Collins KA, Halstead FD, Bliss CM, Ewer KJ, Osier FH, Hodgson SH, Duncan CJ, O'Hara GA, Long CA, Hill AV, Draper SJ.

PLoS One. 2014 Sep 25;9(9):e107903. doi: 10.1371/journal.pone.0107903. eCollection 2014.

9.

Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults.

Ogwang C, Afolabi M, Kimani D, Jagne YJ, Sheehy SH, Bliss CM, Duncan CJ, Collins KA, Garcia Knight MA, Kimani E, Anagnostou NA, Berrie E, Moyle S, Gilbert SC, Spencer AJ, Soipei P, Mueller J, Okebe J, Colloca S, Cortese R, Viebig NK, Roberts R, Gantlett K, Lawrie AM, Nicosia A, Imoukhuede EB, Bejon P, Urban BC, Flanagan KL, Ewer KJ, Chilengi R, Hill AV, Bojang K.

PLoS One. 2013;8(3):e57726. doi: 10.1371/journal.pone.0057726. Epub 2013 Mar 19.

10.

CD8+ T effector memory cells protect against liver-stage malaria.

Reyes-Sandoval A, Wyllie DH, Bauza K, Milicic A, Forbes EK, Rollier CS, Hill AV.

J Immunol. 2011 Aug 1;187(3):1347-57. doi: 10.4049/jimmunol.1100302. Epub 2011 Jun 29.

11.

Development of a chimeric Plasmodium berghei strain expressing the repeat region of the P. vivax circumsporozoite protein for in vivo evaluation of vaccine efficacy.

Espinosa DA, Yadava A, Angov E, Maurizio PL, Ockenhouse CF, Zavala F.

Infect Immun. 2013 Aug;81(8):2882-7. doi: 10.1128/IAI.00461-13. Epub 2013 May 28.

12.

Protective antibody and CD8+ T-cell responses to the Plasmodium falciparum circumsporozoite protein induced by a nanoparticle vaccine.

Kaba SA, McCoy ME, Doll TA, Brando C, Guo Q, Dasgupta D, Yang Y, Mittelholzer C, Spaccapelo R, Crisanti A, Burkhard P, Lanar DE.

PLoS One. 2012;7(10):e48304. doi: 10.1371/journal.pone.0048304. Epub 2012 Oct 29.

13.

Tailoring a Combination Preerythrocytic Malaria Vaccine.

Bauza K, Atcheson E, Malinauskas T, Blagborough AM, Reyes-Sandoval A.

Infect Immun. 2015 Dec 14;84(3):622-34. doi: 10.1128/IAI.01063-15.

14.

A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses.

Prieur E, Gilbert SC, Schneider J, Moore AC, Sheu EG, Goonetilleke N, Robson KJ, Hill AV.

Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):290-5. Epub 2003 Dec 23.

15.

Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines.

Draper SJ, Biswas S, Spencer AJ, Remarque EJ, Capone S, Naddeo M, Dicks MD, Faber BW, de Cassan SC, Folgori A, Nicosia A, Gilbert SC, Hill AV.

J Immunol. 2010 Dec 15;185(12):7583-95. doi: 10.4049/jimmunol.1001760. Epub 2010 Nov 22.

16.

Prime-boost vectored malaria vaccines: progress and prospects.

Hill AV, Reyes-Sandoval A, O'Hara G, Ewer K, Lawrie A, Goodman A, Nicosia A, Folgori A, Colloca S, Cortese R, Gilbert SC, Draper SJ.

Hum Vaccin. 2010 Jan;6(1):78-83. Epub 2010 Jan 18. Review.

PMID:
20061802
17.

A prime-boost immunisation regimen using DNA followed by recombinant modified vaccinia virus Ankara induces strong cellular immune responses against the Plasmodium falciparum TRAP antigen in chimpanzees.

Schneider J, Langermans JA, Gilbert SC, Blanchard TJ, Twigg S, Naitza S, Hannan CM, Aidoo M, Crisanti A, Robson KJ, Smith GL, Hill AV, Thomas AW.

Vaccine. 2001 Sep 14;19(32):4595-602.

PMID:
11535306
18.

Development of a Plasmodium berghei transgenic parasite expressing the full-length Plasmodium vivax circumsporozoite VK247 protein for testing vaccine efficacy in a murine model.

Mizutani M, Fukumoto S, Soubeiga AP, Soga A, Iyori M, Yoshida S.

Malar J. 2016 Apr 30;15(1):251. doi: 10.1186/s12936-016-1297-3.

19.

Vaccine efficacy against malaria by the combination of porcine parvovirus-like particles and vaccinia virus vectors expressing CS of Plasmodium.

Rodríguez D, González-Aseguinolaza G, Rodríguez JR, Vijayan A, Gherardi M, Rueda P, Casal JI, Esteban M.

PLoS One. 2012;7(4):e34445. doi: 10.1371/journal.pone.0034445. Epub 2012 Apr 17.

20.

Combining liver- and blood-stage malaria viral-vectored vaccines: investigating mechanisms of CD8+ T cell interference.

Forbes EK, Biswas S, Collins KA, Gilbert SC, Hill AV, Draper SJ.

J Immunol. 2011 Oct 1;187(7):3738-50. doi: 10.4049/jimmunol.1003783. Epub 2011 Aug 29.

Supplemental Content

Support Center